A) Human exposures have been uncommon and have often involved exposure to arsine and hydrogen sulfide, in addition to stibine. The principal effect of stibine is hemolysis, with secondary effects involving the kidneys and liver. It is anticipated to cause pulmonary irritation, based on animal studies.
B) Exposed humans have experienced headache, weakness, nausea, lumbar pain, jaundice, and hematuria. Signs and symptoms similar to those occurring in shock, seizures and death are suggested effects which are anticipated to occur with severe exposures.
C) Animals exposed to stibine have pulmonary irritation, congestion and edema, hemolysis, secondary renal effects, anemia, and fatty liver changes.
0.2.3 VITAL SIGNS
0.2.3.1 ACUTE EXPOSURE
A) Effects similar to those encountered in shock have been suggested effects. The pulse may be weak and irregular. Dyspnea and/or slowed respirations may be present.
0.2.6 RESPIRATORY
0.2.6.1 ACUTE EXPOSURE
A) Pulmonary irritation is a possible effect based principally on results in animal studies.
0.2.7 NEUROLOGIC
0.2.7.1 ACUTE EXPOSURE
A) Severe headache is a common early symptom of stibine poisoning. Seizures may develop in severe exposures.
0.2.8 GASTROINTESTINAL
0.2.8.1 ACUTE EXPOSURE
A) Nausea and abdominal pain are common.
0.2.9 HEPATIC
0.2.9.1 ACUTE EXPOSURE
A) Jaundice has been reported.
0.2.10 GENITOURINARY
0.2.10.1 ACUTE EXPOSURE
A) Abdominal and lumbar pain are common. Hematuria is an early sign of stibine-induced hemolysis.
0.2.13 HEMATOLOGIC
0.2.13.1 ACUTE EXPOSURE
A) Stibine causes hemolysis. Anemia and significant weakness may be present.
0.2.21 CARCINOGENICITY
0.2.21.1 IARC CATEGORY
A) IARC Carcinogenicity Ratings for CAS7803-52-3 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
1) Not Listed
The information contained in the Truven Health Analytics Inc. products is intended as an educational aid only. All treatments or procedures are intended to serve as an information resource for physicians or other competent healthcare professionals performing the consultation or evaluation of patients and must be interpreted in view of all attendant circumstances, indications and contraindications. The use of the Truven Health Analytics Inc. products is at your sole risk. These products are provided "as is" and "as available" for use, without warranties of any kind, either express or implied. Truven Health Analytics Inc. makes no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the productsAdditionally, Truven Health ANALYTICS INC. makes no representation or warranties as to the opinions or other service or data you may access, download or use as a result of use of the Truven Health ANALYTICS INC. products. All implied warranties of merchantability and fitness for a particular purpose or use are hereby excluded. Truven Health Analytics Inc. does not assume any responsibility or risk for your use of the Truven Health Analytics Inc. products.
